Nuclear Expression of TDP-43 Is Linked with Morphology and Ubiquitylation of Cytoplasmic Aggregates in Amyotrophic Lateral Sclerosis

The transactive response DNA-binding protein of 43 kDa (TDP-43) is a pathological protein of amyotrophic lateral sclerosis (ALS). TDP-43 pathology is characterized by a combination of the cytoplasmic aggregation and nuclear clearance of this protein. However, the mechanisms underlying TDP-43 pathology have not been fully clarified. The aim of this study was to evaluate the relationships between the expression level of nuclear TDP-43 and the pathological properties of cytoplasmic aggregates in autopsied ALS cases. We included 22 consecutively autopsied cases with sporadic TDP-43-related ALS. The motor neuron systems were neuropathologically assessed. We identified 790 neurons with cytoplasmic TDP-43 inclusions from the lower motor neuron system of included cases. Nuclear TDP-43 disappeared in 84% (n = 660) and expressed in 16% (n = 130) of neurons with cytoplasmic inclusions; the former was defined as TDP-43 cytoplasmic immunoreactivity (c-ir), and the latter was defined as nuclear and cytoplasmic immunoreactivity (n/c-ir). Morphologically, diffuse cytoplasmic inclusions were significantly more prevalent in TDP-43 n/c-ir neurons than in c-ir neurons, while skein-like and round inclusions were less prevalent in n/c-ir neurons. The cytoplasmic inclusions of TDP-43 n/c-ir neurons were phosphorylated but poorly ubiquitylated when compared with those of c-ir neurons. TDP-43 n/c-ir neurons became less dominant than the c-ir neurons among cases with a prolonged disease duration. The expression level of nuclear TDP-43 was significantly lower in n/c-ir neurons than in normal neurons without cytoplasmic inclusions. Our results indicate that the maturation of cytoplasmic TDP-43 inclusions correlates with the depletion of nuclear TDP-43 in each affected neuron. This finding supports the view that an imbalance between nuclear and cytoplasmic TDP-43 may be an essential pathway to TDP-43 pathology.

[1]  G. Sobue,et al.  TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links? , 2022, International journal of molecular sciences.

[2]  G. Rouleau,et al.  Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids , 2022, bioRxiv.

[3]  G. Sobue,et al.  Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. , 2022, Brain : a journal of neurology.

[4]  G. Hummer,et al.  Disease‐linked TDP‐43 hyperphosphorylation suppresses TDP‐43 condensation and aggregation , 2022, The EMBO journal.

[5]  G. Hummer,et al.  Disease‐linked TDP‐43 hyperphosphorylation suppresses TDP‐43 condensation and aggregation , 2021, bioRxiv.

[6]  C. Emiliani,et al.  Lysosomal Exocytosis, Exosome Release and Secretory Autophagy: The Autophagic- and Endo-Lysosomal Systems Go Extracellular , 2020, International journal of molecular sciences.

[7]  K. Wakabayashi,et al.  An autopsy case of early‐stage amyotrophic lateral sclerosis with TDP‐43 immunoreactive neuronal, but not glial, inclusions , 2019, Neuropathology : official journal of the Japanese Society of Neuropathology.

[8]  Trees-Juen Chuang,et al.  Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons , 2019, Acta Neuropathologica Communications.

[9]  C. Geula,et al.  Morphology and Distribution of TDP-43 Pre-inclusions in Primary Progressive Aphasia , 2019, Journal of neuropathology and experimental neurology.

[10]  J. Taylor,et al.  Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects , 2019, Proceedings of the National Academy of Sciences.

[11]  Michael J. Steinbaugh,et al.  ALS IMPLICATED PROTEIN TDP-43 SUSTAINS LEVELS OF STMN2 A MEDIATOR OF MOTOR NEURON GROWTH AND REPAIR , 2019, Nature Neuroscience.

[12]  K. Nave,et al.  Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination , 2018, Proceedings of the National Academy of Sciences.

[13]  J. Trojanowski,et al.  Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo , 2018, Nature Communications.

[14]  Matthew A. White,et al.  TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD , 2018, Nature Neuroscience.

[15]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[16]  Chadwick M. Hales,et al.  TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD , 2017, Alzheimer's & Dementia.

[17]  G. Halliday,et al.  ALS/FTLD: experimental models and reality , 2017, Acta Neuropathologica.

[18]  G. Sobue,et al.  Exosome secretion is a key pathway for clearance of pathological TDP-43. , 2016, Brain : a journal of neurology.

[19]  H. Braak,et al.  Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal α-motoneurons in sporadic amyotrophic lateral sclerosis , 2016, Acta Neuropathologica.

[20]  G. Halliday,et al.  Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS , 2015, Acta Neuropathologica.

[21]  Robert H. Brown,et al.  Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis , 2014, Proceedings of the National Academy of Sciences.

[22]  S. Antonyuk,et al.  Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life , 2014, Proceedings of the National Academy of Sciences.

[23]  G. Sobue,et al.  Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2014, JAMA neurology.

[24]  John Q. Trojanowski,et al.  Amyotrophic lateral sclerosis—a model of corticofugal axonal spread , 2013, Nature Reviews Neurology.

[25]  D. Mann,et al.  Prion-like properties of pathological TDP-43 aggregates from diseased brains. , 2013, Cell reports.

[26]  Murray Grossman,et al.  Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis , 2013, Annals of neurology.

[27]  J. Trojanowski,et al.  A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.

[28]  J. Hodges,et al.  Neuropathological background of phenotypical variability in frontotemporal dementia , 2011, Acta Neuropathologica.

[29]  J. Trojanowski,et al.  Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. , 2011, The Journal of clinical investigation.

[30]  H. Akiyama,et al.  Phosphorylated and cleaved TDP‐43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP‐43 proteinopathy , 2010, Neuropathology : official journal of the Japanese Society of Neuropathology.

[31]  M. Piccinini,et al.  TDP‐43 Redistribution is an Early Event in Sporadic Amyotrophic Lateral Sclerosis , 2010, Brain pathology.

[32]  S. Pereson,et al.  TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration , 2010, Proceedings of the National Academy of Sciences.

[33]  D. Dickson,et al.  Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  John L. Robinson,et al.  Clinical and pathological continuum of multisystem TDP-43 proteinopathies. , 2009, Archives of neurology.

[35]  M. Morita,et al.  Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis , 2008, Annals of neurology.

[36]  Hitoshi Takahashi,et al.  Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia , 2008, Acta Neuropathologica.

[37]  J. Trojanowski,et al.  Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease , 2007, Acta Neuropathologica.

[38]  H. Akiyama,et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.

[39]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[40]  T. Dörk,et al.  Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping , 2001, The EMBO journal.

[41]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[42]  Charles E. Ingbert.  An enumeration of the medullated nerve fibers in the dorsal roots of the spinal nerves of man , 1903 .

[43]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.